More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday. Sold ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...